Setterwalls has advised Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of shares of approximately SEK 86 million. The rights issue was subscribed to approximately 163 per cent.
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator’s shares are listed on Nasdaq Stockholm since 2016. The company is headquartered in Lund, Sweden